Strategic investments in technology enable the manufacturing of small, tailored drug batches, demanding flexible facilities for rapid formulation changes. This evolution is optimizing drug customization and elevating patient-centric care in pharmaceutical practices.
In light of this, I evaluated two prominent pharma stocks, SNDL Inc. (SNDL) and GSK plc (GSK), to ascertain which holds the potential to yield superior long-term returns. Let's understand this in detail.
